The report
“Opportunities in Human Embryonic Stem Cell (hESC)
Products – Trends and Forecasts to 2017” by BioInformant Worldwide, L.L.C is now available
at RnRMarketResearch.com.com. Contact sales@rnrmarketresearch.com with report name in subject
line and your contact details to purchase this report or get your questions
answered.
This report is available at a flat
10% Discount on all license types till October 31, 2013. Listed above are
original prices and the discount is applicable on the same.
Stem cells
are primitive cells found in all multi-cellular organisms that are
characterized by self-renewal and the capacity to differentiate into any mature
cell type. Categorized by stage of life, several broad categories of stem cells
exist, including: Embryonic stem cells, derived from blastocysts; Post-natal
stem cells, derived from newborn tissues; Adult stem cells, found in adult
tissues – including hematopoietic stem cells, mesenchymal stem cells, neural
stem cells, and more; Induced pluripotent stem cells, reprogrammed from adult
cells; Cancer stem cells, which give rise to clonal populations of cells that
form tumors or disperse in the body.
Embryonic
stem cells are stem cells derived from the inner cell mass of a blastocyst,
which is a stage reached four to five days post-fertilization. They are the
most pluripotent of all stem cell types and can develop into over 200 different
cell types of the human body. Human embryonic stem cells (hESCs) were first
derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and
independently by Gail R. Martin. In 1995, the first successful culturing of
embryonic stem cells from non-human primates occurred at the University of
Wisconsin-Madison. Another breakthrough followed at the University of
Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson
developed a technique to isolate and grow hESCs derived from human blastocysts.
As such,
embryonic stem cells are still a relatively new discovery, as the first mouse
embryonic stem cells (ESCs) were derived from embryos in 1981, but it was not
until 1995 that the first successful culturing of embryonic stem cells from
non-human primates occurred and not until November 1998 that a technique was
developed to isolate and grow embryonic stem cells from human blastocysts.
Market Segments
To
facilitate research resulting from these advances, a large and diverse market
has emerged for human embryonic stem cell products, platforms, and
technologies. In total, the global sales of these items compose the hESC
product marketplace. One thriving component of this marketplace is the segment
of companies that sell hESC research products to scientists.
Termed
“research supply companies” or “research product vendors,” large companies
selling human embryonic stem cell research products include Life Technologies,
BD Biosciences, Thermo Fisher Scientific, EMD Millipore, Sigma Aldrich, Lonza,
R&D Systems, and STEMCELL Technologies, as well as more than 60 other
suppliers that range in size from multinational corporations to small specialty
companies. Together, these research supply companies represent a substantial
annual percentage of hESC product sales.
As of
2013, the following product categories accounted for more than 85% of all
global hESC research product sales: Embryonic stem cell culture products; Embryonic
stem cell lines; Antibodies to embryonic stem cell antigens; Bead-based
embryonic stem cell separation systems; Embryonic stem cell protein
purification and analysis tools; Tools for DNA and RNA-based characterization
of embryonic stem cells; Embryonic stem cell specific growth factors and
cytokines; Tools for embryonic stem cell gene regulation; Embryonic stem cell
services and mechanisms for in vivo and in vitro stem cell tracking.
In
addition, pharmaceutical companies also have intense interest in human
embryonic stem cell product development. Because of their plasticity and
unlimited capacity for self-renewal, hESCs have been proposed for use in a wide
range of pharmaceutical applications, including: Drug target validation and
testing; Toxicology testing; Tissue engineering; Cellular therapies; Personalized
medicine; And more
For this
reason, development of hESC products by the pharmaceutical sector also
represents a thriving segment of the global hESC product marketplace. Of
particular interest to this community is the potential for use of hESCs to heal
tissues that have a naturally limited capacity for renewal, such as the human
heart, liver and brain.
Furthermore,
within the pharmaceutical sector, development of new drugs is extremely costly
and the success rate of bringing new compounds to the market is unpredictable.
Therefore, it is crucial that pharmaceutical companies minimize late-stage
product failures, such as suboptimal pharmacokinetic properties or unexpected
toxicity, that can arise when candidate drugs enter the clinical testing
stages.
To achieve
this, it would be highly desirable to test candidate drugs using in vitro
assays of high human relevance as early as possible. Because hESCs have the
potential to differentiate into all of the mature cell types of the human body,
they represent an ideal cell type from which to design such drug screening
assays.
In
summary, the unifying factor within the hESC product marketplace is that all
companies involved need to understand market forces, trends, metrics, and
financials, in order out-compete the competition and make more profitable
decisions. Producing hESC products can involve complicated and confusing
decisions, but it doesn’t have to. Claim this report to reveal the current and
future needs of the hESC marketplace, so you can focus your marketing efforts
on the most profitable products, in the most promising research areas, and
within the most lucrative domestic and international markets.
Market Characterization
It is also
crucial for companies involved in the hESC product marketplace to understand
the funding environment which supports hESC research. Within the United States,
the federal government is currently an important, although not dominant, source
of funding for stem cell research. The reason is that U.S. states are spending
almost as much as the federal government on stem cell research and are actually
spending more than the federal government on human embryonic stem cell (hESC)
research. Private sources also contribute a huge amount of funding to stem cell
research, with analysis of recent large gifts summing to over $1.7 billion.
Worldwide,
hESC funding also varies widely, with countries varying from “very permissive”
to “very limited” in how each elects to fund hESC product and technology
development within the federal, private, and not-for-profit sectors.
While
there is conclusive evidence that entering the hESC marketplace is financially
worthwhile, there are complicating factors for companies that hope to enter the
market. Specifically, human embryonic stem cell research is heavily encumbered
by patents held by the University of Wisconsin’s Wisconsin Alumni Research
Foundation (WARF), which creates significant challenges for companies seeking
to develop new products.
As such,
this market research report explores the complex intellectual property (IP)
landscape affecting development of human embryonic stem cell products,
providing clear guidance for companies entering or already within the market,
from collaborating with WARF to less costly alternatives – such as
circumventing the claims, conducting research off-shore, and developing
embryonic stem cell products for other species.
Methods and Methodology
As a
technology company, BioInformant’s standard techniques derive market data from
sources that utilize high-quality primary research inputs. The following
constitute the basis for our research and analysis:
- Preliminary Research - Examination of studies that
need further confirmation by the scientific community, using extensive
secondary research.
- Fill-gap Research - Selectively sampled and
focused primary research as a fill-gap strategy.
- Historic Analysis - Historic analysis of all
end-user industries/markets, requiring technology and market evaluations,
growth projections, and market size estimation of end-user markets.
- Historic Supply Chain/Raw
Materials Analysis - Comprehensive
analysis of data for each primary market segment.
- Data Consolidation - Merging historic end-user
market data to yield consolidated primary market data.
- Cross Linking - Primary market data
(historic) is compared with resulting end-user consolidated market data and the
variance in percentages between data sets is calculated by year.
- Variance Determination – A median figure for each year with
a tolerance range equal to twice the variance percentage is determined.
- Projections - End-user markets are
projected forward (typically 2013-17) based upon historic growth, technology
and market trends, and primary research from the market place.
- Variance Factorization - Consolidation of projected
end-user market data to yield derived primary market data. The data is adjusted
to the historic variance determinations, as above. The resulting data is
further verified by confirmatory primary research.
- Confirmatory Primary Research – Resulting data is presented from
companies or individuals participating as research partners. Variations from
derived data are adjusted to reflect primary research based consensus.
- Electronically Based End-User
Surveys - In
addition to the methods described above, electronically based end-user surveys
are utilized. Surveys are distributed to a comprehensive panel of academic and
industry representatives working within the market segment of interest.
Furthermore,
the market intelligence contained in this report was compiled using a broad
range of sources, including:
- Grant
Funding Databases (NIH database, DoD database, and more)
- Patent
Databases (USPTO, WIPO)
- Scientific
Publication Databases (PubMed, Highwire Press, Google Scholar)
- Product
Launch Announcements (Trade Journals, Company Websites, PR News Feeds)
- Financial
Data (SEC Filings, Investor Relations Packets)
- International
Surveys (Electronically Distributed End-User Surveys)
- And More
Finally, a
rare and valuable feature of this report is an end-user survey of 247
researchers (101 U.S. / 146 International) that identify as having human
embryonic stem cell research as their core research focus. These findings
reveal hESC researcher needs, technical preferences, key factors influencing
buying decisions, and more.
Scientist
survey results include: Emerging trends within the hESC research sector; Insights
into hESC product selection, purchasing decisions, and preferred providers; Crucial
trends and unmet market needs within the hESC marketplace; “Tested Sentences”
for selling to hESC scientists; Breakdown of the marketing methods used by
industry participants; And much more.
Leverage
these insider insights to make effective product development decisions, create
targeted marketing messages, and produce higher prospect-to-client conversion
rates.
Conclusions
In
summary, growth in stem cell research has exploded in the past decade, and so
the market to supply hESC products and technologies has grown to meet this huge
demand. To profit from this rapidly expanding market, you need to understand
your key strengths relative to the competition, intelligently position your
products to fill gaps in the market place, and take advantage of crucial hESC
trends. Claim this must-read industry report to optimally position yourself to
sell hESC products.
Key Findings Include:
- Charts,
Trends, and Metrics for the hESC Product Market
- Trends
for hESC Grants, Scientific Publications, and Patents
- 5-Year
Market Size Projections (2013-2017)
- Profitable
Opportunities for hESC Product and Technology Development
- Consumer
Behavioral Patterns and Preferred Providers
- Preferred
Species for ESC Research
- Crucial
Trends and Unmet Market Needs
- Breakdown
of the Marketing Methods Used by Industry Participants
- “Tested
Sentences” for Selling to hESC Scientists
- End-User
Survey of hESC Researchers (101 U.S. / 146 International)
